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ABSTRACT
Ebola virus disease (EVD) was first identified in 1976 in Yambuku, Zaire (now the 
Democratic Republic of Congo), and is caused by an RNA virus in the filovirus family 
(Feldmann & Geisbert). The current strain circulation in West Africa is very similar 
to the original strain (>95% homology). The origin of the current outbreak remains 
unknown, but it is suspected to be from an animal reservoir with intermediary species 
(Fauci). Randomized clinical trials with adaptive design are ongoing to evaluate 
potential new therapies for EVD.
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Ebola virus disease (EVD) was first identified in 1976 in Yambuku, Zaire 
(now the Democratic Republic of Congo), and is caused by an RNA virus in 
the filovirus family1. The current strain circulating in West Africa is very similar 
to the original strain (>95% homology). The origin of the current outbreak 
remains unknown, but it is suspected to be from an animal reservoir and may 
involve intermediary species2.
EVD has affected more than 27,000 people in West Africa, mostly in Liberia, 
Sierra Leone, and Guinea; the case-fatality rate has ranged from 20-80%, 
with an overall average mortality around 50%3. Transmission occurs through 
direct contact with infected bodily fluids and may be associated with mucosal 
surfaces, skin breaks, and parenteral routes. Contact with patients with 
suspected or confirmed EVD seems to be the strongest independent predictor, 
based on a recent study4. The incubation period varies from 2-21 days, but 
most cases present within the first 7 days. Fever and fatigue are the most 
common initial symptoms in greater than 90% of patients; in addition, arthralgia, 
myalgia, headache, sore throat, anorexia, and rash can be present. After a few 
days, the gastrointestinal symptoms start with nausea, vomiting, abdominal 
pain, and severe diarrhea, with up to 5-10 liters of fluid loss per day. At this 
stage, hypovolemic shock and renal failure may develop quickly, followed 
by multi-organ failure. Coagulation disturbances and bleeding have been 
less common in the current outbreak and tend to occur in the late phases of 
the disease. Laboratory abnormalities include hyponatremia, hypokalemia, 
hypophosphatemia, hypomagnesemia, lymphocytopenia, thrombocytopenia, 
raised liver enzymes, metabolic acidosis, creatinine elevation, increased 
international normalized ratio and d-dimers1,2.
The current outbreak started in April of 2014, and despite substantial 
decrease in the number of new cases in the last few months, the outbreak is still 
ongoing in Sierra Leone and Guinea3. The reasons for such a large outbreak 
in this specific region are multifactorial: 1) decades of geopolitical conflicts; 
2) close country borders with easy mobility among these countries; 3) poor 
healthcare infrastructure (e.g. limited availability of protective equipment, as 
well as of isolation beds); 4) restricted number of healthcare professionals (i.e. 
physicians, nurses, assistants, microbiology and laboratory professionals); 
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5) traditional practices that include bathing of corpses 
before burial; 6) concurrent healthcare outbreaks 
and challenges with other infectious diseases such 
as malaria, HIV, and typhoid fever.
Twenty-six patients with confirmed EVD have 
been evacuated to the European Union and USA 
since the beginning of the outbreak. In the USA there 
are three medical centers that can receive patients 
from Africa who are diagnosed with EVD: University 
of Nebraska Medical Center (Omaha, Nebraska), 
Emory University (Atlanta, Georgia), and the National 
Institutes of Health (Bethesda, Maryland). What these 
centers have in common is a biocontainment unit 
comprised of highly trained medical personnel and 
an infrastructure equipped with specifically designed 
space and materials to deal with highly contagious 
infectious diseases.
Isolation of patients with exposure to Ebola and 
new onset fever maintains public safety and provision 
of proper personal protective equipment (PPE) gives 
the caregiver the confidence to treat this disease. 
The most important factor to maintaining isolation is 
careful attention to the donning and doffing of PPE. 
All caregivers going into the unit had to change 
into scrubs and put on the PPE one would use for 
universal precautions including a surgical mask, 
isolation gown and gloves. Everyone wore slip-on 
rubber shoes with shoe covers that were removed 
upon leaving the unit and dipped in a bleach solution. 
Entering the ‘hot zone’ (patient location) required 
additional PPE and another team member to observe 
the process to make sure there were no breaks in 
the PPE. Doffing was also a two-person job requiring 
decontamination at each step with alcohol hand gel 
and new gloves5. Resources from the University of 
Nebraska Biocontainment Unit are available outlining 
each step of this process6.
Our biocontainment unit at the University of 
Nebraska Medical Center took care of three patients 
diagnosed with Ebola. Optimized supportive care was 
the most immediate and standard treatment offered 
to all patients. It included the placement of peripheral 
and central lines, volume replacement with balanced 
solutions, electrolytes corrections, laboratory and 
microbiological monitoring, verification of RNA viremia 
by polymerase chain reaction techniques, airborne 
and contact isolation techniques. The acuity of the 
patients dictated that a team approach to the physician 
care of these patients be taken. The intensivists 
obtained central venous access, managed fluid and 
electrolytes and nutrition as well as any critical care 
issues that arose. The infectious disease specialists 
worked on the treatment of the virus, health care 
worker protection, equipment decontamination, and 
investigational new drug applications for the Food 
and Drug Administration5.
In addition to the optimized supportive care, the 
patients admitted to the University of Nebraska Medical 
Center received several investigational drugs as 
compassionate use through the FDA: convalescent 
plasma, small interfering RNA nanoparticles, polymerase 
inhibitors, and monoclonal antibodies7,8. The problem 
with uncontrolled administration of investigational 
drugs is that inferences about the effects of these 
potential therapies are very difficult to make since 
many factors can contribute to the survival or demise 
of these patients with EVD: patients’ own immune 
system, quality of supportive care, and effects of 
specific investigational drugs7. The only way to 
make more reliable inferences about efficacy is by 
providing these investigational drugs in the setting 
of randomized controlled studies. Fortunately, the 
National Institutes of Health (Bethesda, Maryland), in 
conjunction with the University of Nebraska Medical 
Center, Emory University, and several hospitals in 
both Liberia and Sierra Leone, designed and started a 
randomized clinical trial to test several investigational 
drugs sequentially based on an innovative trial 
design denominated Bayesian adaptive design9. 
This randomized clinical trial is currently ongoing and 
enrolling patients in order to evaluate the first drug: 
the monoclonal antibody combination called ZMapp10. 
The adaptive design requires a smaller number of 
patients than conventional design to reach efficacy 
and safety endpoints. Once the conclusion of benefits 
(or lack of) is reached, the second investigational 
drug will be automatically started without any clinical 
trial interruption. If ZMapp proves to be beneficial, 
then this drug will become incorporated as part of the 
standard of care to be utilized in the next study step 
(sequential administration of the second investigational 
drug to be tested); if ZMapp does not cause benefit 
or causes harm, this drug will be removed from the 
trial, and then the second investigational drug will be 
tested against the same standard of care used in the 
first part of the study. Of note, both the American and 
African sites that are participating in this new clinical 
trial will not offer these investigational drugs to their 
patients outside the context of the clinical trial. We 
believe that this robust and appropriate trial design 
approach will maximize the chances to discover new 
cures for this devastating disease, as well as to be 
prepared for future outbreaks.
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